NCT06360458进行中（未招募）3 期
Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Strokes With Large Infarct: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial (MIRACLE)
Wan-Jin Chen99 个研究点 分布在 1 个国家目标入组 928 人开始时间: 2024年8月1日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 928
- 试验地点
- 99
- 主要终点
- All-cause mortality at 90 (±14) days
研究概览
简要总结
The efficacy and safety of methylprednisolone in acute ischemic stroke patients with large infarct cores (ASPECTS score < 6 or infarct volume ≥50 mL) due to anterior circulation large vessel occlusion have not been clearly established. This is a multi-center, randomized, double-blind, placebo-controlled trial to investigate early combination therapy with methylprednisolone for reperfusion in acute large core infarction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •The time from onset to randomization was within 12 hours.
- •Anterior circulation ischemic stroke was preliminarily determined according to clinical symptoms or imaging examination.
- •Occlusion of the intracranial internal carotid artery, the M1- or M2-segment of the middle cerebral artery by confirmed by CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA).
- •Baseline National Institutes of Health Stroke Scale (NIHSS) ≥
- •Baseline Alberta Stroke Program Early CT Score (ASPECTS) < 6 (based on non-contrast CT or MRI) and/or core infarct volume ≥ 50 ml (based on CTP with rCBF < 30%).
- •Planned treatment with endovascular thrombectomy (EVT).
- •Informed consent obtained from patients or their legal representatives.
排除标准
- •Intracranial hemorrhage confirmed by cranial CT or MRI.
- •mRS score > 2 before onset.
- •Pregnant or lactating women.
- •Allergic to contrast agents or glucocorticoids.
- •Participating in other clinical trials.
- •The artery is tortuous so that the thrombectomy device cannot reach the target vessel.
- •Bleeding history (gastrointestinal and urinary tract bleeding) in recent 1 month.
- •Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate < 30 ml/min or serum creatinine > 220 umol/L [2.5 mg/ dL]).
- •Life expectancy due to any advanced disease < 6 months.
- •Follow-up is not expected to be completed.
- •Intracranial aneurysm and arteriovenous malformation.
- •Brain tumors with imaging mass effect.
- •Systemic infectious disease.
研究组 & 干预措施
Placebo group
Placebo Comparator
Methylprednisolone sodium succinate simulant
干预措施: Placebo (Drug)
结局指标
主要结局
All-cause mortality at 90 (±14) days
时间窗: From randomization to 90 (±14) days
Primary Efficacy Outcome. Defined as the number of any cause deaths observed divided by the number of subjects observed over the 90-day study period.
次要结局
- Time from randomization to the occurrence of death from any cause at 90 (±14) days(From randomization to 90 (±14) days)
- mRS ordinal shift at 90 (±14) days (scores 5 and 6 are merged)(From randomization to 90 (±14) days)
- Proportion of patients with mRS score 0 to 4 at 90 (±14) days(From randomization to 90 (±14) days)
- Proportion of patients with mRS score 0 to 3 at 90 (±14) days(From randomization to 90 (±14) days)
- Proportion of patients with mRS score 0 to 2 at 90 (±14) days(From randomization to 90 (±14) days)
- Proportion of patients with mRS score 0 to 1 at 90 (±14) days or return to pre-stroke mRS score (for patients with pre-stroke mRS > 1)(From randomization to 90 (±14) days)
- Midline shift at 48 hours(From randomization to 48 hours)
- Proportion of patients with midline shift >5 mm within 48 hours after EVT(From randomization to 48 hours)
- Relative hemispheric volume at 48 hours(From randomization to 48 hours)
- Net water uptake at 48 hours(From randomization to 48 hours)
- Proportion of patients with decompressive craniectomy after EVT(From randomization until the date of discharge, an average of 1 week)
- NIHSS score at 5-7 days or at early discharge(From randomization to 5-7 days ( or at early discharge))
- EQ-5D-5L VAS at 90 (±14) days(From randomization to 90 (±14) days)
- Proportion of patients with symptomatic intracranial haemorrhage (SICH) within 48 hours after EVT(From randomization to 48 hours)
- Proportion of patients with any intracranial haemorrhage (ICH) within 48 hours after EVT(From randomization to 48 hours)
- Proportion of patients with pneumonia(From randomization until the date of discharge, an average of 1 week)
- Proportion of patients with gastrointestinal haemorrhage within 7 days after EVT(From randomization to 7 days)
- Incidence of any complications(From date of randomization until the date of discharge, an average of 1 week)
- Incidence of any (serious) adverse events(From randomization to 90 (±14) days)
研究者
Wan-Jin Chen
Vice President of Fujian Medical University and Vice President of The First Affiliated Hospital of Fujian Medical University
First Affiliated Hospital of Fujian Medical University
研究点 (99)
Loading locations...
相似试验
进行中（未招募）
1 期
Efficacy of methylprednisolone pulses in neuroendocrine cells hyperplasia of infancy: an early phase study (CORTICONEHI).EUROENDOCRINE CELLS HYPERPLASIA OF INFANCYMedDRA version: 21.1Level: PTClassification code: 10072968Term: Neuroendocrine cell hyperplasia of infancy Class: 100000004855MedDRA version: 20.0Level: SOCClassification code: 10038738Term: Respiratory thoracic and mediastinal disorders Class: 13CTIS2023-508132-65-00Assistance Publique Hopitaux De Paris19
已完成
不适用
Preoperative Methylprednisolone in Endovascular Aortic RepairAbdominal Aortic AneurysmsNCT00989729Louise de la Motte150
招募中
不适用
Efficacy and safety of methylprednisolone pulse therapy for ocular myasthenia gravis: a pilot studyocular myasthenia gravisJPRN-jRCTs051200137Koh Jinsoo10
已完成
不适用
Coagulation After Intravenous Methylprednisolone AdministrationGraves' DiseaseGraves OphthalmopathyBlood CoagulationVenous ThromboembolismNCT03535090Piotr Miskiewicz26
已完成
2 期
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion TherapiesStroke, AcuteStroke, IschemicBrain DiseasesStrokeNCT05920889Chinese University of Hong Kong140